Treatments and outcomes of untreated cerebral cavernous malformations in China: study protocol of a nationwide multicentre prospective cohort study

Fuxin Lin, Qiu He, Zhuyu Gao, Lianghong Yu, Dengliang Wang, Shufa Zheng, Yuanxiang Lin, Dezhi Kang, Fuxin Lin, Qiu He, Zhuyu Gao, Lianghong Yu, Dengliang Wang, Shufa Zheng, Yuanxiang Lin, Dezhi Kang

Abstract

Introduction: The treatment decision and long-term outcomes of previously untreated cerebral cavernous malformation (U-CCM) are still controversial. Therefore, we are conducting a nationwide multicentre prospective registry study in China to determine the natural history and effect of surgical treatment on long-term outcomes in Chinese people with U-CCM.

Methods and analysis: This study was started on 1 January 2018 and is currently ongoing. It is a cohort follow-up study across a 5-year period. Patients will be followed up for at least 3 years after inception. Patients with U-CCM will be enrolled from 24 Grade III, level A hospitals distributed all over China. The cohort size is estimated to be 1200 patients. Patients are registered in surgically treated group and conservatively treated group. Clinical characteristics, radiology information and laboratory data are prospectively collected using an electronic case report form through an electronic data capture system. The primary outcome of this study is poor clinical outcome at the last follow-up (modified Rankin Scale score >2 lasting at least 1 year). The secondary outcome includes symptomatic haemorrhage, drug refractory epilepsy, focal neurological deficits, morbidity and all-cause mortality during follow-up. Univariate and multivariate regression analysis will be performed to determine the risk factors for poor outcomes in all patients, and to estimate the effect of surgery. Life tables, Kaplan-Meier estimates, log-rank test and proportional hazards Cox regression will be used to analyse the follow-up data of conservatively treated patients to determine the natural history of U-CCM. Initial presentation and location of U-CCM are prespecified subgroup factors.

Ethics and dissemination: The study protocol and informed consent form have been reviewed and approved by the Research Ethical Committee of First Affiliated Hospital of Fujian Medical University (FAHFMU-2018-003).Written informed consent will be obtained from each adult participant or from the guardian of each paediatric participant. The final results will be published in peer-reviewed journals.

Trial registration number: NCT03467295.

Keywords: clinical trials; neurosurgery; protocols & guidelines; vascular surgery.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
The geographical location and full names of the 24 subcentres of this study.
Figure 2
Figure 2
Diagram of the study protocol. U-CCM, untreated cerebral cavernous malformation.

References

    1. Al-Shahi Salman R, Kitchen N, Thomson J, et al. . Top ten research priorities for brain and spine cavernous malformations. Lancet Neurol 2016;15:354–5. 10.1016/S1474-4422(16)00039-9
    1. Akers A, Al-Shahi Salman R, A Awad I, et al. . Synopsis of guidelines for the clinical management of cerebral cavernous malformations: consensus recommendations based on systematic literature review by the angioma alliance scientific Advisory board clinical experts panel. Neurosurgery 2017;80:665–80. 10.1093/neuros/nyx091
    1. Morris Z, Whiteley WN, Longstreth WT, et al. . Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2009;339:b3016. 10.1136/bmj.b3016
    1. Al-Shahi Salman R, Hall JM, Horne MA, et al. . Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study. Lancet Neurol 2012;11:217–24. 10.1016/S1474-4422(12)70004-2
    1. Horne MA, Flemming KD, Su I-C, et al. . Clinical course of untreated cerebral cavernous malformations: a meta-analysis of individual patient data. Lancet Neurol 2016;15:166–73. 10.1016/S1474-4422(15)00303-8
    1. Al-Shahi Salman R, Berg MJ, Morrison L, et al. . Hemorrhage from cavernous malformations of the brain: definition and reporting standards. angioma alliance scientific Advisory board. Stroke 2008;39:3222–30. 10.1161/STROKEAHA.108.515544
    1. Zhang L, Yang W, Jia W, et al. . Comparison of outcome between surgical and conservative management of symptomatic spinal cord cavernous malformations. Neurosurgery 2016;78:552–61. 10.1227/NEU.0000000000001075
    1. Kwan P, Arzimanoglou A, Berg AT, et al. . Definition of drug resistant epilepsy: consensus proposal by the AD hoc Task force of the ILAE Commission on therapeutic strategies. Epilepsia 2010;51:1069–77. 10.1111/j.1528-1167.2009.02397.x
    1. Poorthuis M, Samarasekera N, Kontoh K, et al. . Comparative studies of the diagnosis and treatment of cerebral cavernous malformations in adults: systematic review. Acta Neurochir 2013;155:643–9.
    1. Bicalho VC, Bergmann A, Domingues F, et al. . Cerebral cavernous malformations: patient-reported outcome validates conservative management. Cerebrovasc Dis 2017;44:313–9. 10.1159/000480125
    1. Dammann P, Wrede K, Jabbarli R, et al. . Outcome after conservative management or surgical treatment for new-onset epilepsy in cerebral cavernous malformation. J Neurosurg 2017;126:1303–11. 10.3171/2016.4.JNS1661
    1. Lee Y, Cho KH, Kim HI, et al. . Clinical outcome following medical treatment of cavernous malformation related epilepsy. Seizure 2017;45:64–9. 10.1016/j.seizure.2016.11.009
    1. Moultrie F, Horne MA, Josephson CB, et al. . Outcome after surgical or conservative management of cerebral cavernous malformations. Neurology 2014;83:582–9. 10.1212/WNL.0000000000000684
    1. Zaidi HA, Mooney MA, Levitt MR, et al. . Impact of timing of intervention among 397 consecutively treated brainstem cavernous malformations. Neurosurgery 2017;81:620–6. 10.1093/neuros/nyw139
    1. Garcia RM, Ivan ME, Lawton MT. Brainstem cavernous malformations: surgical results in 104 patients and a proposed grading system to predict neurological outcomes. Neurosurgery 2015;76:265–77. 10.1227/NEU.0000000000000602
    1. Pandey P, Westbroek EM, Gooderham PA, et al. . Cavernous malformation of brainstem, thalamus, and basal ganglia: a series of 176 patients. Neurosurgery 2013;72:573–89. 10.1227/NEU.0b013e318283c9c2
    1. Li D, Jiao Y-M, Wang L, et al. . Surgical outcome of motor deficits and neurological status in brainstem cavernous malformations based on preoperative diffusion tensor imaging: a prospective randomized clinical trial. J Neurosurg 2018;130:286–301. 10.3171/2017.8.JNS17854
    1. Lin Y, Lin F, Kang D, et al. . Supratentorial cavernous malformations adjacent to the corticospinal tract: surgical outcomes and predictive value of diffusion tensor imaging findings. J Neurosurg 2018;128:541–52. 10.3171/2016.10.JNS161179
    1. Lin F, Wu J, Wang L, et al. . Surgical treatment of cavernous malformations involving the posterior limb of the internal capsule: utility and predictive value of preoperative diffusion tensor imaging. World Neurosurg 2016;88:538–47. 10.1016/j.wneu.2015.10.074

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir